RAREUltragenyx Pharmaceutical Inc

Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm PR Newswire NEW YORK, June 4, 2026 NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Key PointsKrensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter...

Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.

Wells Fargo & Company upped their price target on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an "overweight" rating in a research report on Wednesday...

Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a 'neutral' rating for the company in a research report on Wednesday...

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 84.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,094 shares of the...

Ultragenyx Pharmaceutical (NASDAQ:RARE) executives said the company is positioned for what Chief Executive Officer Emil Kakkis described as a "transformative" year, pointing to expectations for growing revenue, potential approvals for two gene therapies, and a key late-stage readout for its Angelman...

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $999.00 EPS for the quarter, beating analysts' consensus estimates of ($1.50) by $1,000.50. Ultragenyx Pharmaceutical had a negative return on equity of...